Beremagene geperpavec

DB17831ApprovedInvestigationalGene Therapies

Beremagene geperpavec is gene therapy used to treat wounds associated with dystrophic epidermolysis bullosa. Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy.

Mechanism
Curator reviewed · 8 references
Primary indication
Beremagene geperpavec (Vyjuvek) is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, in individuals from birth.Curator reviewed · 2 structured indications
First approval
United States, 2023
Also known as
B-VEC · Bercolagene telserpavec · BVEC · Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
Code names
KB-103 · KB803
Brand names
  • Vyjuvek

Resolves to

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Beremagene geperpavec, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account